Rani Therapeutics Raises $69 Million Series E To Advance Clinical Trials And Manufacturing Of Robotic Pill

Rani Therapeutics, a clinical-stage biopharmaceutical company and developer of the RaniPill™ robotic pill, today announced that it has raised $69 million in a Series E financing, bringing the total funding to $211 million. BofA Securities acted as financial advisor to the company. The investment will accelerate clinical development of Rani's internal pipeline drugs and allow the company to scale up manufacturing. In addition to building its own pipeline of drugs, Rani has partnerships with Novartis and Takeda. About Rani TherapeuticsRani Therapeutics has developed the RaniPill™ robotic pill, an oral biologics platform designed to replace injectable biologics. The RaniPill™ is a pain-free alternative for subcutaneous injections, eliminating one of the biggest obstacles to patient compliance. Rani has a strong patent position with more than 280 patents filed. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R D lab focused on breakthrough medical innovations. Rani and InCube are founded by Mir Imran, a prolific medical inventor, entrepreneur, and investor.
（以上内容由医药魔方AI生成）